DALLAS, Oct. 1, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc. ("Nanoscope"), a biotechnology company focused on developing and commercializing novel, disease–agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted for review, and granted priority review to, the Company's New Drug Application (NDA) seeking marketing approval from the Ministry of Health, Labour and Welfare (MHLW) of MOGENRY®(sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy designed for vision restoration, for the treatment of inherited retinal dystrophies (IRDs).
Read more at prnewswire.comNanoscope Therapeutics Announces PMDA Acceptance and Priority Review of New Drug Application for MOGENRY® in Japan for the Treatment of Inherited Retinal Dystrophies
Barchart·10/01/2026 06:04:00
語音播報
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.